Radiolabeled Peptides: Valuable Tools for the Detection and Treatment of Cancer
Open Access
- 1 January 2012
- journal article
- Published by Ivyspring International Publisher in Theranostics
- Vol. 2 (5), 481-501
- https://doi.org/10.7150/thno.4024
Abstract
Human cancer cells overexpress many peptide receptors as molecular targets. Radiolabeled peptides that bind with high affinity and specificity to the receptors on tumor cells hold great potential for both diagnostic imaging and targeted radionuclide therapy. The advantage of solid-phase peptide synthesis, the availability of different chelating agents and prosthetic groups and bioconjugation techniques permit the facile preparation of a wide variety of peptide-based targeting molecules with diverse biological and tumor targeting properties. Some of these peptides, including somatostatin, bombesin, vasoactive intestinal peptide, gastrin, neurotensin, exendin and RGD are currently under investigation. It is anticipated that in the near future many of these peptides may find applications in nuclear oncology. This article presents recent developments in the field of small peptides, and their applications in the diagnosis and treatment of cancer.Keywords
This publication has 100 references indexed in Scilit:
- [ 64 Cu-NOTA-8-Aoc-BBN(7-14)NH 2 ] targeting vector for positron-emission tomography imaging of gastrin-releasing peptide receptor-expressing tissuesProceedings of the National Academy of Sciences of the United States of America, 2007
- Effects of linker variation on the in vitro and in vivo characteristics of an 111In-labeled RGD peptideNuclear Medicine and Biology, 2007
- αvβ3 Integrin‐targeting of intraperitoneally growing tumors with a radiolabeled RGD peptideInternational Journal of Cancer, 2006
- Radiolabeled somatostatin receptor antagonists are preferable to agonists forin vivopeptide receptor targeting of tumorsProceedings of the National Academy of Sciences of the United States of America, 2006
- Clinical applications of newer radionuclide therapiesEuropean Journal of Cancer, 2006
- 213Bi-[DOTA0, Tyr3]Octreotide Peptide Receptor Radionuclide Therapy of Pancreatic Tumors in a Preclinical Animal ModelClinical Cancer Research, 2006
- Noninvasive Visualization of the Activated αvβ3 Integrin in Cancer Patients by Positron Emission Tomography and [18F]Galacto-RGDPLoS Medicine, 2005
- Improved Tumor Targeting of Radiolabeled RGD Peptides Using Rapid Dose FractionationCancer Biotherapy & Radiopharmaceuticals, 2004
- Role of integrins in angiogenesisEuropean Journal Of Cancer, 1996
- Cloning and Functional Characterization of a Family of Receptors for the Melanotropic PeptidesAnnals of the New York Academy of Sciences, 1993